Title
Author
DOI
Article Type
Special Issue
Volume
Issue
Deadline for manuscript submissions: 30 June 2021
Print Special Issue Flyer (2)Francesco Plotti, MD, PhDE-MailWebsite
Campus Biomedico University of Rome, Rome, Italy
Interests: Gynecologyc Oncology; Minimally Invasive Surgery; Preinvasive Disease; Tumor Markers
Dear Colleagues,
In the last 10 years, new markers for the management of gynecological tumors has entered powerfully in the world literature. Tumor markers are soluble glycoproteins that are found in the blood, urine, or tissues of patients with certain types of cancer. They are typically produced by tumor cells, but in some cases they may be produced by the body in response to malignancy or to certain benign conditions. Tumor markers are not elevated in all cancer patients, particularly patients with early-stage cancer. The various tumor markers differ in their usefulness for screening, diagnosis, prognosis, assessing therapeutic response, and detecting recurrence.The aim of this comprehesnsive review is to gather all the evidence reported in literature analysing the potential value of tumor markers in every step of the management of gynecologic cancers and evaluate the new possible strategies for targeting growth-dependent mechanisms involved in its pathogenesis.
Prof. Dr. Francesco Plotti
Guest Editor
Ovarian cancer;Endometrial cancer;Cervical cancer;Tumor markers;Follow up;Prognosis;Target therapy
Effectiveness of human epididymis protein 4 (HE4) as predictor of response to first line platinum based chemotherapy
DOI: 10.31083/j.ejgo4205129
(This article belongs to the Special Issue The Role of Biomarker in Gynecological Oncology)